Drug Profile
HCP 1202
Alternative Names: HCP-1202Latest Information Update: 28 Nov 2018
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease in South Korea
- 25 Oct 2016 Hanmi Pharmaceutical Company plans a phase III trial for Chronic obstructive pulmonary disease in South Korea (NCT02941679)
- 10 Oct 2015 Phase-I clinical trials in Chronic obstructive pulmonary disease in South Korea (unspecified route)